The Business Research Company’s market reports offer an in-depth analysis on the market’s growth potential, major drivers, key trends and more.
Strong Market Growth in Recent Years
- The bioinformatics in in vitro diagnostics (IVD) testing market has seen robust growth.
- Market size increased from $87.25 billion in 2023 to $93.02 billion in 2024.
- This growth, with a compound annual growth rate (CAGR) of 6.6%, can be attributed to several factors:
- Improved healthcare infrastructure.
- Expansion of biobanks.
- Rising geriatric population.
- Government initiatives and funding.
- Growth of personalized medicine.
Future Market Projections: Continued Expansion
- The market is projected to grow to $121.57 billion by 2028, at a CAGR of 6.9%.
- Key drivers in the forecast period include:
- Rising prevalence of diseases.
- Integration of IT in healthcare.
- Government initiatives and funding.
- A shift towards personalized medicine.
- Enhanced awareness among healthcare providers.
- Decreasing cost of genomic sequencing.
Read More On The Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market Report 2024 – https://www.thebusinessresearchcompany.com/report/bioinformatics-in-in-vitro-diagnostics-ivd-testing-global-market-report
Trends Shaping the Future
- Artificial Intelligence (AI) and Machine Learning: Transforming data analysis and diagnostics.
- Next-Generation Sequencing (NGS): Revolutionizing genetic analysis.
- Point-of-Care (POC) Testing: Enhancing accessibility and convenience.
- Cloud Computing and Big Data: Facilitating large-scale data analysis.
- Innovations in Immunochemical Techniques: Improving diagnostic accuracy.
Rising Chronic Diseases Propel Market Growth
Impact of Increasing Cancer Prevalence
- Cancer rates are rising globally, expected to reach 28.4 million cases by 2040, a 47% increase from 2020.
- Factors driving this increase include exposure, lifestyle, and environmental influences.
- Bioinformatics in IVD testing plays a crucial role in cancer diagnostics by:
- Providing precise, personalized genetic insights.
- Enhancing early detection.
- Informing treatment decisions.
- Improving patient outcomes.
Role of Bioinformatics in Cancer Detection
- Bioinformatics tools in IVD testing allow for comprehensive analysis, aiding in the early detection of cancer.
- This technology supports personalized medicine, tailoring treatment plans based on individual genetic profiles.
Major Players in the Market
- Leading companies in the bioinformatics in IVD testing market include:
- Siemens Healthineers
- International Business Machines Corporation
- Medtronic Inc.
- Illumina Inc.
- QIAGEN N.V.
- PerkinElmer Inc.
- Bioreference Laboratories Inc.
- These companies are driving innovation and expansion in the market, contributing to its rapid growth.
Revolutionizing Genetic Analysis with NGS Technology
Advancements in Next-Generation Sequencing (NGS)
- Major companies focus on developing next-generation sequencing (NGS) technology.
- NGS allows for rapid sequencing of entire genomes or specific DNA/RNA regions.
- This technology improves:
- Detection and analysis of genetic mutations.
- Diagnostic accuracy.
- Personalized medicine approaches.
Case Study: Illumina’s Innovations
- In May 2022, Illumina Inc. launched the TruSight Oncology Comprehensive (EU) test.
- This pan-cancer companion diagnostic (CDx) identifies cancer patients with neurotrophic tyrosine receptor kinase (NTRK) gene fusions.
- The test aids in targeted therapy, showcasing the power of NGS in cancer treatment.
Accelerating Cancer Diagnosis: Illumina’s Acquisition of GRAIL
Strategic Acquisition for Enhanced Diagnostics
- In August 2021, Illumina Inc. acquired GRAIL to accelerate cancer diagnosis.
- GRAIL specializes in bioinformatics for IVD testing, particularly in cancer detection.
- This acquisition aims to:
- Speed up patient access to diagnostic tools.
- Enable the identification of multiple cancer types using a single blood sample.
Regional Insights and Market Segmentation
North America Leading, Asia-Pacific Rising
- North America was the largest region in the bioinformatics in IVD testing market in 2023.
- Asia-Pacific is expected to be the fastest-growing region during the forecast period, driven by:
- Expanding healthcare infrastructure.
- Increased government initiatives and funding.
- Rising demand for personalized medicine.
Market Segmentation
- The bioinformatics in IVD testing market is segmented by:
- Type: Hardware, Software.
- Type of Test: Blood-Based Tests, Tissue-Based Tests.
- Application: Cardiovascular Diseases, Chronic Diseases, Diabetes, Cancer, Other Applications.
Conclusion: A Market Poised for Growth
- The bioinformatics in IVD testing market is set for continued growth, driven by advancements in technology, rising disease prevalence, and increasing focus on personalized medicine.
- As companies innovate and expand, the market will continue to play a critical role in enhancing diagnostic accuracy and improving patient outcomes.
Request for A Sample Of The Global Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market Report:
https://www.thebusinessresearchcompany.com/sample_request?id=16629&type=smp